NCT02529930 - An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions

High Grade Cervical Intraepithelial Neoplasia

Interventions

BIOLOGICAL

VB10.16 Immunotherapy (DNA vaccine)

Patients will receive 3 vaccinations of 3 mg VB10.16 at the pre-specified time points. VB10.16 will be administered intramuscularly in the area over the lateral deltoid muscle.

Trial Locations (4)

20246

Universitätsklinikum Hamburg-Eppendorf, Hamburg

30159

IZD Institut für Zytologie und Dysplasie, Hanover

30625

Medical School Hanover, Hanover

38440

Klinikum Wolfsburg, Wolfsburg